271 related articles for article (PubMed ID: 22046311)
61. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.
Eslava I; Payares G; Pernia BM; Holder AA; Spencer LM
Malar J; 2010 Feb; 9():46. PubMed ID: 20146804
[TBL] [Abstract][Full Text] [Related]
62. Immune responses mediating survival of naive BALB/c mice experimentally infected with lethal rodent malaria parasite, Plasmodium yoelii nigeriensis.
Singh B; Nayak BP; Rao KV; Sharma P
Microbes Infect; 2000 Apr; 2(5):473-80. PubMed ID: 10865192
[TBL] [Abstract][Full Text] [Related]
63. Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles.
Dutta S; DasSarma P; DasSarma S; Jarori GK
Malar J; 2015 Oct; 14():406. PubMed ID: 26463341
[TBL] [Abstract][Full Text] [Related]
64. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model.
Rotman HL; Daly TM; Clynes R; Long CA
J Immunol; 1998 Aug; 161(4):1908-12. PubMed ID: 9712060
[TBL] [Abstract][Full Text] [Related]
65. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
66. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
[TBL] [Abstract][Full Text] [Related]
67. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
68. Correlation of increased expression of intercellular adhesion molecule-1, but not high levels of tumor necrosis factor-alpha, with lethality of Plasmodium yoelii 17XL, a rodent model of cerebral malaria.
Shear HL; Marino MW; Wanidworanun C; Berman JW; Nagel RL
Am J Trop Med Hyg; 1998 Dec; 59(6):852-8. PubMed ID: 9886187
[TBL] [Abstract][Full Text] [Related]
69. Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice.
Amante FH; Good MF
Parasite Immunol; 1997 Mar; 19(3):111-26. PubMed ID: 9106817
[TBL] [Abstract][Full Text] [Related]
70. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Kedzierski L; Black CG; Coppel RL
Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
[TBL] [Abstract][Full Text] [Related]
71. Adoptive transfer of CD8+ T cells from immune animals does not transfer immunity to blood stage Plasmodium yoelii malaria.
Vinetz JM; Kumar S; Good MF; Fowlkes BJ; Berzofsky JA; Miller LH
J Immunol; 1990 Feb; 144(3):1069-74. PubMed ID: 1967271
[TBL] [Abstract][Full Text] [Related]
72. Serum antibody immunoglobulin G of mice convalescent from Plasmodium yoelii infection inhibits growth of Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved in interspecies cross-reactive inhibition of parasite growth.
Ray P; Sahoo N; Singh B; Kironde FA
Infect Immun; 1994 Jun; 62(6):2354-61. PubMed ID: 8188358
[TBL] [Abstract][Full Text] [Related]
73. Caspase-12 deficiency enhances cytokine responses but does not protect against lethal Plasmodium yoelii 17XL infection.
Miu J; Saleh M; Stevenson MM
Parasite Immunol; 2010; 32(11-12):773-8. PubMed ID: 21086719
[TBL] [Abstract][Full Text] [Related]
74. Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kilodalton rhoptry proteins protects mice against Plasmodium yoelii blood-stage challenge infection.
Narum DL; Ogun SA; Batchelor AH; Holder AA
Infect Immun; 2006 Oct; 74(10):5529-36. PubMed ID: 16988228
[TBL] [Abstract][Full Text] [Related]
75. Production of interleukin 10 during malaria caused by lethal and nonlethal variants of Plasmodium yoelii yoelii.
Kobayashi F; Morii T; Matsui T; Fujino T; Watanabe Y; Weidanz WP; Tsuji M
Parasitol Res; 1996; 82(5):385-91. PubMed ID: 8738275
[TBL] [Abstract][Full Text] [Related]
76. Immunological studies in rodent malaria. I: Protective immunity induced in mice by mild strains of Plasmodium berghei yoelii against a virulent and fatal line of this plasmodium.
Hargreaves J; Yoeli M; Nussenzweig RS
Ann Trop Med Parasitol; 1975 Sep; 69(3):289-99. PubMed ID: 1098589
[TBL] [Abstract][Full Text] [Related]
77. Kinetics of antigen specific and non-specific polyclonal B-cell responses during lethal Plasmodium yoelii malaria.
Rolland L; Ballet JJ; Daniel-Ribeiro C
Mem Inst Oswaldo Cruz; 1992; 87(2):197-204. PubMed ID: 1284989
[TBL] [Abstract][Full Text] [Related]
78. Cytokine and antibody production during the course of resolution in Plasmodium yoelii 17XL-infected BALB/c mice treated with febrifugine and isofebrifugine mixture from leaves of Hydrangea macrophylla var. Otaksa.
Ishih A; Nagata T; Kobayashi F; Miyase T; Terada M
Parasitol Res; 2004 Oct; 94(3):176-82. PubMed ID: 15338283
[TBL] [Abstract][Full Text] [Related]
79. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.
Dinga JN; Gamua SD; Ghogomu SM; Titanji VPK
Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29284177
[TBL] [Abstract][Full Text] [Related]
80. Mycobacterium-induced potentiation of type 1 immune responses and protection against malaria are host specific.
Page KR; Jedlicka AE; Fakheri B; Noland GS; Kesavan AK; Scott AL; Kumar N; Manabe YC
Infect Immun; 2005 Dec; 73(12):8369-80. PubMed ID: 16299335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
